Egenesis Overview
- Founded
- 2015

- Status
- Private
- Employees
- 54

- Latest Deal Type
- Series B
- Latest Deal Amount
- $100M

- Investors
- 14
Egenesis General Information
Description
Developer of a gene transplantation platform designed to address the global organ crisis. The company's platform performs gene editing and genome engineering to provide an alternative source of safe and effective human-compatible organs, enabling patients with end-stage organ disease to recover and lead a healthy life.
Contact Information
- 300 Technology Square
- Suite 301
- Cambridge, MA 02139
- United States
Egenesis Timeline
Egenesis Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
4. Early Stage VC (Series B) | 01-Nov-2019 | $100M | 00000 | 00000 | Completed | Generating Revenue |
3. Later Stage VC (Series A3) | 02-Aug-2019 | 0000 | Completed | Generating Revenue | ||
2. Early Stage VC (Series A2) | 18-Jun-2018 | $38M | Completed | Generating Revenue | ||
1. Early Stage VC (Series A1) | 13-Mar-2017 | $38M | $38M | 000.00 | Completed | Generating Revenue |
Egenesis Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
---|---|---|---|---|---|---|---|---|
Series B | 00,000,000 | 00.000000 | 00.00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
Series A | 00,000,000 | 00.000000 | 00.00 | 00.0 | 00.0 | 00 | 00.0 | 00.000 |
Egenesis Comparisons
Industry
00000000
0000000
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialEgenesis Competitors (27)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Cellecta | Private Debt Financed | Mountain View, CA | 00 | 000000000 - | ||
0000000 | Venture Capital-Backed | Beijing, China | 000 | 00000 | 00000000000 | 00000 |
000000000 | Venture Capital-Backed | Gaithersburg, MD | 00 | 000.00 | 00000000000 | 000.00 |
00000000 000000000 | Formerly VC-backed | Cambridge, MA | 000 | 0000 | 000000 - 000 | 0000 |
00000000 000000000 | Formerly VC-backed | Bedford, MA | 000 | 00000 | 00000000 | 00000 |
Egenesis Executive Team (12)
Egenesis Board Members (10)
Name | Representing | Role | Since |
---|---|---|---|
Albert Wiegman II | Fresenius Medical Care Ventures | Board Member | 000 0000 |
Bob More | Self | Board Member | 000 0000 |
Boris Nikolic MD | Biomatics Capital | Board Member | 000 0000 |
Daniel Lynch | Self | Executive Chairman | 000 0000 |
Julie Sunderland | Self | Board Member | 000 0000 |
Egenesis Signals
Growth Rate

Growth

Size Multiple


Key Data Points
Twitter Followers
5.5k

Similarweb Unique Visitors
15.0K

Majestic Referring Domains
314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialEgenesis Investors (14)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
Fresenius Medical Care Ventures | Corporate Venture Capital | Minority | 000 0000 | 000000 0 | |
Leaps by Bayer | Corporate Venture Capital | Minority | 000 0000 | 000000 0 | |
Wellington Partners | Venture Capital | Minority | 000 0000 | 000000 0 | |
Alexandria Venture Investments | Corporate Venture Capital | Minority | 000 0000 | 000000 0 | |
Alta Partners | Venture Capital | Minority | 000 0000 | 000000 0 |
Egenesis Acquisitions (1)
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
00000000 | 20-May-2020 | 000000000000000000 | Drug Discovery | 0000 000000 |